



Name

Kuan-Pin Su, M.D., Ph.D.

Current Positions

- Deputy Superintendent, An-Nan Hospital, China Medical University, Tainan (2020/3-)
- Professor of Psychiatry and Neurosciences (2012/11-), College of Medicine, China Medical University (CMU)
- Director, Mind-Body Interface Research Centre, China Medical University Hospital (2006/08-)
- Chief, Department of General Psychiatry, China Medical University Hospital (2002/3-)
- Honorary Professor of Institute of Psychiatry-King's College London (2008/11-)

Telephone

+886-22052121#4126

E-mail

cobolsu@gmail.com

E-Portfolio Website

http://webap.cmu.edu.tw/TchEportfolio/index_1/cobol

Personal Website

<https://sites.google.com/site/omega3su/home>

Education

- 1988-1995, M.D., Kaohsiung Medical College, Kaohsiung, Taiwan
- 2005-2008, PhD, Institute of Psychiatry, King's College London, UK

Expertise

Cognitive Neuropsychology, Cognitive and Behavioral Neuroscience, Mood disorders, Psychopharmacology, Biological Psychiatry

Research Interests

My group focuses on *Translational Brain Research*, which connects bedside to bench with novel interdisciplinary approaches AI technology, neuroimages, genomic, randomized-controlled trials (RCTs), cellular and molecular biology, by integrating clinical significance (e.g. pharmaceuticals, nutraceuticals, phytochemicals, rTMS and acupuncture) with the investigation of basic sciences.

Selected Grants:

- The 10th Mind-Body Interface International Symposium (2020, MOST 109-2916-I-039-004-A1)
- Glymphatic system, microvascular lesion and omega-3 fatty acids in aging-related psychopathology. (2020, MOST109-2320-B-039 -066)
- Microinfarcts and omega-3 fatty acids in aging-related psychopathology: An exploratory clinical and pre-clinical study (2020, MOST108-2314-B-039-048)
- Enhance International Influence: Nutritional Neuroscience as Mainstream of Psychiatry (2018-2021, MOST107-2911-I-039 -503; 107-2911-I-039 -501)
- The 9th Mind-Body Interface International Symposium (2019, MOST 108-2916-I-039 -001-A1)
- The 8th Mind-Body Interface International Symposium (2018, MOST 107-2916-I-039-002-A1)
- Biological mechanisms and clinical subtyping for comorbidity of chronic pain and depression: The molecular approach of central sensitization. (2017-2020, MOST106-2314-B-039-027-MY3)
- N-3 fatty acids as the first-line antidepressant therapy: From biomarkers to clinical subtypes (2016-2018, 3-Year Innovative Research Grant (IRG) of Integrated Research Grants in Health and Medical Sciences from National Health Research Institutes NHRI-EX105-10528NI)

Selected Publications

1. Chang JPC, Su KP*. Nutritional Neuroscience as Mainstream of Psychiatry: The Evidence-Based Treatment Guidelines for Using Omega-3 Fatty Acids as a New Treatment for Psychiatric Disorders in Children and Adolescents. **Clinical Psychopharmacology and Neuroscience** (Accepted)
2. Yang B., Ren XL, Li ZH, Shi MQ, Ding F, Su KP, Guo XJ, Li D. Lowering effects of fish oil supplementation on proinflammatory markers in hypertension: results from a randomized controlled trial. *Food & Function* 2020; 11(2): 1779-1789.
3. Chang JP, Chang SS, Yang HT, Chen HT, Chien YC, Yang B, Su H, Su KP*. Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder – Results from a randomized controlled trial. *Brain Behavior and Immunity* 2020 Mar; 85: 14-20.
4. Borsini A, Nicolaou A, Camacho-Munoz MD, Su KP, Zunszain PA, Pariante CM. Rescue of Interferon (IFN)-Alpha-Induced Reduction of Human Neurogenesis and Increase in Apoptosis by Omega-3 Fatty Acids. *Biological Psychiatry* 2020 May; 87(9): S39.
5. Shityakov S, Chang JPC, Sun CF, Guu TW, Dandekar T, Su KP. Supervised Machine Learning Models and Protein-protein Interaction Network Analysis of Gene Expression Profiles Induced by Omega-3 Polyunsaturated Fatty Acids. **Researchsquare** 2020 Aug; doi: <https://doi.org/10.21203/rs.3.rs-49619/v2>
6. Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, Marx W, Pariante C, Berk M, Jacka F, Su KP*. Corrigendum to “A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder” . [J Affect Disord. 15 (2020) 233-238]. **Journal of Affective Disorders** 2020 Sep; 274:1226-1227.
7. Kim SW, Su KP*. Using psychoneuroimmunity against COVID-19. **Brain Behavior and Immunity** 2020 July. 87: 45. doi: 10.1016/j.bbi.2020.03.025.
8. Liu Y, Li H, Wang J, Xue Q, Yang X, Kang Y, Li M, Xu J, Li G, Li C, Chang HC, Su KP*, Wang F. Association of Cigarette Smoking With Cerebrospinal Fluid Biomarkers of Neurodegeneration, Neuroinflammation, and Oxidation. **JAMA Network Open**. 2020 Oct 1;3(10):e2018777.
9. Wu Y, Brooke L, John P I, Andrea B, Brett D T, Su KP, et al. DEPRESsion Screening Data (DEPRESSD) Collaboration. Probability of Major Depression Classification Based on the SCID, CIDI, and MINI Diagnostic Interviews: A Synthesis of Three Individual Participant Data Meta-Analyses. **Psychotherapy and Psychosomatics** 2020 Jun 1-13. DOI:10.1159/000509283.
10. Liu YL, Li H, Li GH, Kang YM, Shi JP, Kong TT, Yang XY, Xu JZ, Li CB, Su KP*, Wang F. Active smoking, sleep quality and cerebrospinal fluid biomarkers of neuroinflammation. **Brain Behavior and Immunity** 2020 Oct 89,623-627. doi.org/10.1016/j.bbi.2020.07.021
11. Chang JPC, Pariante CM, Su KP*. Omega-3 fatty acids in the psychological and physiological resilience against COVID-19. **Prostaglandins Leukotrienes and Essential Fatty Acids** 2020 Oct 161,102177.
12. Chou PH, Lu MK, Tsai CH, Hsieh WT, Lai HC, Shityakov S, Su KP*. Antidepressant Efficacy and Immune Effects of Bilateral Theta Burst Stimulation Monotherapy in Major Depression: A Randomized, Double-Blind, Sham-Controlled Study. **Brain Behavior and Immunity** 2020 Aug; 88:144-150.
13. Lin YW, Wu AIC, Su HX, Su KP*. Transient receptor potential V1 (TRPV1) modulates the therapeutic effects for comorbidity of pain and depression: The common molecular implication for electroacupuncture and omega-3 polyunsaturated fatty acids. **Brain Behavior and Immunity** 2020 Oct; 89: 604-614.
14. Sun CF, Chiu WC, Chen PC, Chang HC, Guu TW, Shitya S, Miller AH, Felger C, Chang JPC, Su KP. Depression-free after Interferon- α Exposure Indicates Less Incidence of Depressive disorder: A Longitudinal Study in Taiwan. **Brain Behavior and Immunity** 2020 Aug; 88: 125-131. <https://doi.org/10.1016/j.bbi.2020.05.044>

15. Chang JPC, V Mondelli, SK Satyanarayanan, YJ Chiang, HT Chen, Su KP*, Pariante CM. Cortisol, Inflammatory Biomarkers and Neurotrophins in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) in Taiwan. **Brain Behavior and Immunity** 2020 Aug; 88: 105-113. <https://doi.org/10.1016/j.bbi.2020.05.017>
16. Luo XD, Feng JS, Yang Z, Huang OT, Lin JD, Yang B, Su KP*, Pan JY. High-dose omega-3 polyunsaturated fatty acid supplementation might be more superior than low-dose for major depressive disorder in early therapy period: a network meta-analysis. **BMC Psychiatry** 2020 May; 20: 248.
17. Tseng PT, Yang CP, Su KP, Chen TY, Wu YC, Tu YK, Lin PY, Stubbs B, Carvalho AF, Matsuoka YJ, Li DJ, Liang CS, Hsu CW, Chen YW, Shiue YL. The association between melatonin and episodic migraine: a pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. **J Pineal Res.** 2020 Apr 29; 69(2): 1-13. doi: 10.1111/jpi.12663.